nirmatrelvir and ritonavir (Paxlovid)

Following SMC collaboration with NICE on MTA TA878: casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19:

nirmatrelvir and ritonavir (Paxlovid®) is accepted for restricted use within NHSScotland.

Indication under review: treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.

SMC restriction:

Patients with any of the following

• increased risk for progression to severe COVID-19, as defined in section 5 of NICE final guidance
• age 70 years and over
• a body mass index (BMI) of 35 kg/m² or more
• diabetes
• heart failure

_______________________________________________________________________________________________________________________________________

The partial view of TA878 includes a Funding Variation for NHS England. Scottish Government has issued separate advice regarding implementation of this aspect for NHSScotland.